Matches in SemOpenAlex for { <https://semopenalex.org/work/W2401738013> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2401738013 endingPage "143" @default.
- W2401738013 startingPage "S12" @default.
- W2401738013 abstract "The combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given by 3-hour infusion followed by carboplatin infused over 30 minutes has been evaluated in a series of phase I studies and is currently being explored in a phase II study in patients with limited- and extensive-stage small cell lung cancer. Pharmacokinetic measurements were performed at all dose levels in the phase I studies, in which the use of granulocyte colony-stimulating factor in previously treated patients enabled more than twice the dose of paclitaxel to be given with low to moderate doses of carboplatin (dosed to a target area under the concentration-time curve of 4.0 mg x min x mL[-1]). Treatment-naive patients tolerated high paclitaxel doses (270 mg/m2) with carboplatin (dosed to a target area under the curve of 4.5 mg x min x mL[-1]) without granulocyte colony-stimulating factor support. Twenty-three patients (including previously treated and untreated) with non-small cell lung cancer were entered at a variety of paclitaxel doses in the phase I studies. At 100 to 205 mg/m2 paclitaxel, none of nine treated patients responded; at 230 to 290 mg/m2, four (29%) of 14 responded. In the phase II study of paclitaxel 250 mg/m2 in previously untreated patients with small cell lung cancer, two of five evaluable patients with extensive-stage disease have shown a partial response. In a preliminary analysis of the pharmacodynamics of paclitaxel in relation to neurotoxicity (dose limiting in two of three phase I studies), neurotoxicity correlated with the total dose of paclitaxel, the area under the curve, and the peak paclitaxel concentration, but not with the length of time plasma paclitaxel levels remained above 0.05 micromol/L. These correlations were not strong, however, and analysis of these data is ongoing." @default.
- W2401738013 created "2016-06-24" @default.
- W2401738013 creator A5004776795 @default.
- W2401738013 creator A5028257767 @default.
- W2401738013 creator A5055990171 @default.
- W2401738013 creator A5085328645 @default.
- W2401738013 creator A5088972279 @default.
- W2401738013 creator A5090156519 @default.
- W2401738013 date "1997-08-01" @default.
- W2401738013 modified "2023-09-26" @default.
- W2401738013 title "Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer." @default.
- W2401738013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9331139" @default.
- W2401738013 hasPublicationYear "1997" @default.
- W2401738013 type Work @default.
- W2401738013 sameAs 2401738013 @default.
- W2401738013 citedByCount "3" @default.
- W2401738013 countsByYear W24017380132013 @default.
- W2401738013 crossrefType "journal-article" @default.
- W2401738013 hasAuthorship W2401738013A5004776795 @default.
- W2401738013 hasAuthorship W2401738013A5028257767 @default.
- W2401738013 hasAuthorship W2401738013A5055990171 @default.
- W2401738013 hasAuthorship W2401738013A5085328645 @default.
- W2401738013 hasAuthorship W2401738013A5088972279 @default.
- W2401738013 hasAuthorship W2401738013A5090156519 @default.
- W2401738013 hasConcept C111113717 @default.
- W2401738013 hasConcept C112705442 @default.
- W2401738013 hasConcept C121608353 @default.
- W2401738013 hasConcept C126322002 @default.
- W2401738013 hasConcept C126894567 @default.
- W2401738013 hasConcept C143998085 @default.
- W2401738013 hasConcept C2776256026 @default.
- W2401738013 hasConcept C2776694085 @default.
- W2401738013 hasConcept C2777292972 @default.
- W2401738013 hasConcept C2777767877 @default.
- W2401738013 hasConcept C2778239845 @default.
- W2401738013 hasConcept C2781451048 @default.
- W2401738013 hasConcept C31760486 @default.
- W2401738013 hasConcept C71924100 @default.
- W2401738013 hasConcept C76318530 @default.
- W2401738013 hasConcept C90924648 @default.
- W2401738013 hasConcept C98274493 @default.
- W2401738013 hasConceptScore W2401738013C111113717 @default.
- W2401738013 hasConceptScore W2401738013C112705442 @default.
- W2401738013 hasConceptScore W2401738013C121608353 @default.
- W2401738013 hasConceptScore W2401738013C126322002 @default.
- W2401738013 hasConceptScore W2401738013C126894567 @default.
- W2401738013 hasConceptScore W2401738013C143998085 @default.
- W2401738013 hasConceptScore W2401738013C2776256026 @default.
- W2401738013 hasConceptScore W2401738013C2776694085 @default.
- W2401738013 hasConceptScore W2401738013C2777292972 @default.
- W2401738013 hasConceptScore W2401738013C2777767877 @default.
- W2401738013 hasConceptScore W2401738013C2778239845 @default.
- W2401738013 hasConceptScore W2401738013C2781451048 @default.
- W2401738013 hasConceptScore W2401738013C31760486 @default.
- W2401738013 hasConceptScore W2401738013C71924100 @default.
- W2401738013 hasConceptScore W2401738013C76318530 @default.
- W2401738013 hasConceptScore W2401738013C90924648 @default.
- W2401738013 hasConceptScore W2401738013C98274493 @default.
- W2401738013 hasIssue "4 Suppl 12" @default.
- W2401738013 hasLocation W24017380131 @default.
- W2401738013 hasOpenAccess W2401738013 @default.
- W2401738013 hasPrimaryLocation W24017380131 @default.
- W2401738013 hasRelatedWork W1983784941 @default.
- W2401738013 hasRelatedWork W2001963789 @default.
- W2401738013 hasRelatedWork W2036269881 @default.
- W2401738013 hasRelatedWork W2068516756 @default.
- W2401738013 hasRelatedWork W2158532310 @default.
- W2401738013 hasRelatedWork W2401738013 @default.
- W2401738013 hasRelatedWork W2408170581 @default.
- W2401738013 hasRelatedWork W2470668180 @default.
- W2401738013 hasRelatedWork W2802659363 @default.
- W2401738013 hasRelatedWork W3012190538 @default.
- W2401738013 hasVolume "24" @default.
- W2401738013 isParatext "false" @default.
- W2401738013 isRetracted "false" @default.
- W2401738013 magId "2401738013" @default.
- W2401738013 workType "article" @default.